PERTH, Australia – Australia's Therapeutic Goods Administration (TGA) reported a mixed review for its annual performance for drugs and devices covering the period from July 2016 to June 2017 compared to the previous year. Although the agency approved roughly the same number of new chemical entities (NCEs) during 2016 to 2017, approval timelines rose compared to the previous year. Even so, the agency said it reviewed all drugs and devices within the specified legislated time frames.
PERTH, Australia – Australia's Therapeutic Goods Administration (TGA) reported a mixed review for its annual performance for drugs and devices covering the period from July 2016 to June 2017 compared to the previous year.
PERTH, Australia – New listings of higher-priced innovative drugs on Australia's government-subsidized Pharmaceutical Benefit Scheme (PBS) illustrate the government's commitment to list new innovative drugs, and pharma companies will see improved commercial opportunities in Australia, according to a recent BMI Research report.
PERTH, Australia – The process to get innovative new drugs listed on Australia's Pharmaceutical Benefits Scheme (PBS) can be a long and arduous process, and pharma companies waiting to get innovative drugs listed will continue to face mounting pressure and lengthy price negotiations.
PERTH, Australia – New listings of higher-priced innovative drugs on Australia's government-subsidized Pharmaceutical Benefit Scheme (PBS) illustrate the government's commitment to list new innovative drugs, and pharma companies will see improved commercial opportunities in Australia, according to a recent BMI Research report.
PERTH, Australia – The process to get innovative new drugs listed on Australia's Pharmaceutical Benefits Scheme (PBS) can be a long and arduous process, and pharma companies waiting to get innovative drugs listed will continue to face mounting pressure and lengthy price negotiations.
PERTH, Australia – Australian biotech company Clinical Genomics Pty Ltd., of Sydney, will be able to dramatically expand the U.S. footprint of its liquid biopsy diagnostic to detect recurrent colon cancer following a new pact with the Netherlands-based Qiagen NV for its Paxgene blood collection system.
PERTH, Australia – Australian biotech company Clinical Genomics Pty Ltd., based in Sydney, will be able to dramatically expand the U.S. footprint of its liquid biopsy diagnostic to detect recurrent colon cancer following a new pact with the Netherlands-based Qiagen NV for its Paxgene blood collection system.
